Evaluation of the Vaginal Colonization of Two New Lactobacillus Strains After Oral Administration in Healthy Volunteers
Study Details
Study Description
Brief Summary
Randomized study to determine whether the vaginally isolated strains of Lactobacillus gasseri and/or Lactobacillus crispatus can colonize the vagina when taken orally for 18 days. Secondary outcomes comprise evaluation of safety, tolerability, impact on vaginal microbiota and vaginal pH
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Double blind, randomized, placebo-controlled biomedical research study to determine whether supplementation with the vaginally isolated strains of Lactobacillus gasseri and/or Lactobacillus crispatus can colonize the vagina. Healthy women who meet inclusion and exclusion criteria will be randomized 1.5:1.5:1 to one of the following study groups: group one will receive L.gasseri for 18 days (1 capsule/day), group two will recieve the combination of L.gasseri and L.Crispatus for 18 days (1 capsule/day) and the other will receive placebo, starting the day after menstruation is over. Main study outcome will be colonization throughout the study, which will be determined by analysis of specific strains by qPCR. Secondary outcomes comprise comprise evaluation of tolerability, impact on vaginal microbiota, vaginal pH and adverse events.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Experimental 1 L. gasseri oral capsule |
Dietary Supplement: Experimental 1
L. gasseri oral capsule once a day (1 x 10^9 CFU/day) for 18 days starting the next day after menstruation is over
Other Names:
|
| Experimental: Experimental 2 L. gasseri + L. crispatus oral capsule |
Dietary Supplement: Experimental 2
L. gasseri and L. crispatus oral capsule once a day (1.5 x 10^9 CFU/day) for 18 days starting the next day after menstruation is over
Other Names:
|
| Placebo Comparator: Placebo Maltodextrin (E1400, qs) oral capsule once a day |
Dietary Supplement: Placebo
One maltodextrin-containing capsule a day for 18 days starting the next day after menstruation is over
|
Outcome Measures
Primary Outcome Measures
- Colonization of L. crispatus strain in the vagina [0,15 or 18 days]
Change in the concentration of L. crispatus strain throughout study period measured by qPCR in samples obtained with vaginal swab
- Colonization of L. gasseri strain in the vagina [0,15 or 18 days]
Change in the concentration of L. gasseri strain throughout study period measured by qPCR in samples obtained with vaginal swab
Secondary Outcome Measures
- Vaginal colonization of L. gasseri strain [Day 0, 3, 6, 9, 12, 15]
Change in the vaginal concentration of L. gasseri strain measured by qPCR versus baseline
- Vaginal colonization of L. crispatus strain [Day 0, 3, 6, 9, 12, 15]
Change in the vaginal concentration of L. crispatus strain measured by qPCR versus baseline
- Vaginal microbiota composition [Day 0, 6, 12 and 15 or 18]
Change in vaginal microbiota composition measured by 16S rRNA sequencing analysis in samples obtained from vaginal swabs
- Perianal concentration of L. crispatus strain [Day 0, 9 and 15 or 18]
Change in the perianal concentration of L. crispatus strain measured by qPCR
- Perianal concentration of L. gasseri strain [Day 0, 9 and 15 or 18]
Change in the perianal concentration of L. gasseri strain measured by qPCR
- Vaginal pH [Day 0, 3, 6, 9, 12, 15, 18]
Change in vaginal pH throughout study period measured by pH test strip
- Gastrointestinal symptoms [day 0, day 18]
Gastrointestinal manifestations measured on a 4-point scale: 0 = none , 1 = mild, 2 = moderate, and 3 = severe.
- Adverse events [18 days]
Frequency of adverse events throughout study period
- Satisfaction with the product [Day 18]
Evaluation of the satisfaction with the product through the Treatment Satisfaction Questionnaire for Medication (TSQM)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Healthy women
-
Reproductive age 18-45 years
Exclusion Criteria:
-
Vaginal infection or symptoms (AMSEL criteria).
-
Relevant disease (immunodeficiency, cervicovaginal pathology, diabetes, estrogen-dependent tumors, inflammatory bowel disease, atrophic vaginitis, pancreatitis)
-
Suffer from chronic diarrhea or constipation or short bowel syndrome,
-
Having taken systemic or vaginal antibiotics or antifungals during the month prior to study entry.
-
Pregnant women or willing to be during the study, lactating women.
-
Having taken another probiotic during the month prior to study entry orally or vaginally. This includes food supplements or foods supplemented with probiotics such as Actimel, Activia or similar.
-
Intake of immunomodulators or systemic corticosteroids.
-
History of alcohol or drug abuse.
-
Menopausal women.
-
Use of the IUD.
-
Use of spermicides or vaginal lubricants during the month prior to study entry.
-
Very irregular periods or low probability of going at least 18 days without menstruation (short cycles).
-
Have participated in a clinical trial during the month prior to entering the study.
-
Not being able to follow or understand study procedures. This includes not being willing to maintain sexual abstinence during the 24 hours prior to each vaginal sample collection.
-
Any other condition not compatible with the study according to the investigators
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Instituto Hospital del Mar de Investigaciones Médicas | Barcelona | Spain |
Sponsors and Collaborators
- AB Biotics, SA
Investigators
- Principal Investigator: Ana Maria Aldea Perona, PhD, Instituto Hospital del Mar de Investigaciones Médicas
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- OLIVIA